✦ LIBER ✦

A cost/effective schedule with triple therapy in “naive” patients with chronic hepatitis C genotype 2 or 3 and adverse prognostic factors

✍ Scribed by M. Tabone; C. Laudi; L. Sidoli; A. Lavagna; C. Zaffino; A. Pera

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIN62 Cost-Effectiveness of Triple Thera

✍ J.T. Stahmeyer; S. Schauer; D. Wirth; J. Fleischmann; S. Lee; S. Gavart; F. Bian 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

P730 ADVERSE EVENTS AND CO-MEDICATION: A

✍ Schott, E.; Schober, A.; Link, R.; Weber, B.; Rieke, A.; Moog, G.; Spengler, U.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 60 KB

COST-EFFECTIVENESS OF TELAPREVIR COMBINA

✍ Kaczor, M.P.; Wójcik, R.; Pawlik, D.; Skrzekowska-Baran, I.; Tronczynski, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

1042 EFFICACY AND SAFETY RESULTS OF ALBI

✍ Nelson, D.; Benhamou, Y.; Chuang, W.L.; Lawitz, E.; Flisiak, R.; Rodriguez-Torre 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

[645] EARLY VIRAL KINETICS IN PATIENTS W

✍ Th-M. Scherzer; K. Staufer; P. Steindl-Munda; H. Holzmann; P. Ferenci 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Peginterferon-α-2a (40KD) and Ribavirin

✍ Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 173 KB